Clofibric acid
产品说明书
 |
同义名 : | 氯贝酸;对氯苯氧异丁酸;2-(4-氯苯氧基)异丁酸 ;Chlorofibrinic acid;NSC 1149;CCRIS9254 Chlorfibrinic acid;CCRIS 9254;BRN 1874067 |
| CAS号 : | 882-09-7 | |
| 货号 : | A299870 | |
| 分子式 : | C10H11ClO3 | |
| 纯度 : | 98% | |
| 分子量 : | 214.645 | |
| MDL号 : | MFCD00004192 | |
| 存储条件： |
Pure form Sealed in dry,Room Temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(489.18 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 1 mg/mL(4.66 mM)，配合低频超声，并水浴加热至45℃助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Clofibric acid (Chlorofibrinic acid), the active metabolite derived from lipid regulators such as Clofibrate, Etofibrate, and Etofyllinclofibrate, acts as a PPARα agonist and is known for its hypolipidemic effects. Additionally, Clofibric acid is used as an herbicide[1].[2].[3]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00144937 | Peripheral Arterial Disease ... 展开 >> Hypercholesterolemia Hypertension Diabetes Mellitus Smoking 收起 << | Phase 4 | Unknown | - | Spain ... 展开 >> Hospital de Sabadell Sabadell, Barcelona, Spain, 08208 收起 << |
| NCT03031821 | Prostate Cancer ... 展开 >> Metabolic Syndrome 收起 << | Phase 3 | Not yet recruiting | June 1, 2023 | Canada, British Columbia ... 展开 >> BC Cancer Agency - Vancouver Cancer Centre Not yet recruiting Vancouver, British Columbia, Canada, V5Z 4E6 Contact: Bernie Eigl, MD 604-877-6000 bernie.eigl@bccancer.bc.ca Principal Investigator: Bernie Eigl, MD 收起 << |
| NCT01047501 | Hypertriglyceridemia | Phase 3 | Completed | - | - |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
4.66mL 0.93mL 0.47mL |
23.29mL 4.66mL 2.33mL |
46.59mL 9.32mL 4.66mL |
| 参考文献 |
|---|